---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-028807"
form_type: "8-K"
ticker: "HCWB"
cik: "0001828673"
company_name: "HCW Biologics Inc."
filed_at: "2026-06-16T11:15:40+00:00"
generated_at: "2026-06-16T11:20:34.846863+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# HCW Biologics Reports Positive Preliminary Human Data for HCW9302 Phase 1 Trial in Alopecia Areata

## Summary
- All three patients in second dose cohort (3 µg/kg) showed ≥25% reduction in SALT scores after single dose, indicating clinical response.
- No dose-limiting toxicities, capillary leak, cytokine release syndrome, or increased eosinophil counts reported; only mild injection-site reactions.
- Company projects to establish Recommended Phase 2 Dose by year-end 2026 and is dosing third cohort (8 µg/kg).
- HCW9302 is a first-in-kind IL-2 based fusion immunotherapeutic with strong IL-2Rα bias, potentially best-in-class for autoimmune diseases.
- CEO Hing C. Wong stated results consistent with preclinical studies showing Treg expansion and reduced inflammation.

## SEC filing metadata
- accession: 0001493152-26-028807
- form_type: 8-K
- ticker: HCWB
- cik: 0001828673
- company_name: HCW Biologics Inc.
- filed_at: 2026-06-16T11:15:40+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828673/000149315226028807/0001493152-26-028807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828673/000149315226028807/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-028807
- JSON: https://secwatch.observer/filing/0001493152-26-028807.json
- Plain text: https://secwatch.observer/filing/0001493152-26-028807.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.